Why bone marrow transplants are becoming less common
Bone marrow transplants, long a mainstay of blood cancer treatments, are becoming less common in favor of options like CAR-T therapy
Related Articles
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
PURPOSEIn patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), brentuximab vedotin (BV) as monotherapy or combined with either lenalidomide (Len) or rituximab…
T cell malignancies after CAR T cell therapy in the DESCAR-T registry
Nature Medicine – This analysis of the registry database DESCAR-T of more than 3,000 pediatric and adult patients with hematological malignancies who received CAR T cell…
Galapagos to split itself into two companies as part of turnaround plan
The beleaguered Belgian firm Galapagos is splitting itself into two companies, with the brandname biotech prioritizing oncology.
With a major patent cliff coming, will JPM play host to some serious deal-making?
The drug industry is facing one of the largest patent cliffs in recent history. Will that mean dealmaking at the annual J.P. Morgan Healthcare Conference.
Leaving FDA, Califf is unapologetic — and warns of staff departures
In an interview, outgoing FDA commissioner Robert Califf was wary of the Trump administration but unapologetic about controversial decision during his term.
AI in medicine: preparing for the future while preserving what matters
2025 is here and medicine has continued to move away from the utopian vision of our admission essays for medical school. We are spending countless…
Program Guide – ASCO Meeting Program Guide
Presenter: Elizabeth Nally, BSc, MBBS Presenter: Atulya Aman Khosla, MD, MBBS Presenter: Annalis a Guida, MD Presenter: Alan Pollack, MD, PhD Presenter: Sean Ryan Miller,…
Using lab-grown human mini-brains, scientists find links between head trauma, herpes, and Alzheimer’s
Research published Tuesday is the first to connect the dots between a common herpes virus, head injury, and Alzheimer’s.
How one foundation changed its approach to diversify grant recipient institutions
The Beckman Foundation wanted to make sure it wasn’t unfairly prioritizing elite research institutions. So it tried something new: dual anonymization in peer review.
As academic Bluesky grows, researchers find strengths—and shortcomings
Platform fosters collegial interactions among scientists, but potentially limits interactions beyond the academic community